EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis

Jordan T Brooks iD, Belén P Solans iD, Agathe Béranger iD, H Simon Schaaf iD, Louvina van der Laan iD, Sangeeta Sharma, Jennifer Furin, Heather R Draper, Anneke C Hesseling iD, Anthony J Garcia-Prats iD, Radojka M Savic

Clinical Infectious Diseases · 17.12.2024 · 79 (6) · 1495-1502

DOI: 10.1093/cid/ciae497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 18.10.2024. Verfasst von Jordan T Brooks und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of California-San Francisco, Department of Bioengineering and Therapeutics, School of Pharmacy, San Francisco, California, USA. Hauptthemen laut MEDLINE: Linezolid, Anemia, Rifampin, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BENEFIT Kids.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Linezolid, a component of rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) treatment, is associated with treatment-limiting toxicities, including anemia. Patient-level and linezolid pharmacokinetic risk factors for anemia have not been well described in children treated for RR/MDR-TB.

Methods

We evaluated the pharmacokinetics of linezolid and longitudinal hemoglobin data to validate an existing population linezolid pharmacokinetic model. We assessed the impact of linezolid pharmacokinetics and the risk of developing anemia in a prospectively enrolled cohort of children. A previously published population pharmacokinetic linezolid model was validated using nonlinear mixed effects modeling. A multivariable ordinal logistic regression model was built to predict the incidence of anemia.

Results

A total of 112 children, median age 7.2 years (interquartile range, 2.2–16.3), were included from South Africa (n = 87) and India (n = 25). Of these, 24 children contributed new linezolid pharmacokinetic data. The population pharmacokinetic model, which informs the currently recommended linezolid dosing in children (10–15 mg/kg), was validated with these additional new data. For every 1 g/dL lower baseline hemoglobin level, the odds of developing grade 3 or 4 anemia increased by 2.64 (95% confidence interval [CI], 1.98–3.62). For every 1 mg/L × h higher linezolid area under the concentration-time curve, the odds of developing grade 3 or 4 anemia increased by 1.012 (95% CI, 1.007–1.017).

Conclusions

Taken together, these data confirm currently recommended linezolid doses for children. The risk of anemia in children should be carefully considered and monitored. Initiating linezolid in children with low baseline hemoglobin increases the probability of experiencing grade 3 or 4 anemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidAnemiaRifampinTuberculosis, Multidrug-ResistantHumansChildChild, PreschoolMaleFemaleAdolescentProspective StudiesAntitubercular AgentsSouth AfricaIndiaRisk Factors

Stichwörter der Autor:innen

anemiachildrendosinglinezolidpharmacokinetics

Substanzen

LinezolidRifampinAntitubercular Agents

Autor:innen und Institutionen

  • University of California-San Francisco, Department of Bioengineering and Therapeutics, School of Pharmacy, San Francisco, California, USA.
  • University of California-San Francisco, Department of Bioengineering and Therapeutics, Schools of Pharmacy and Medicine, San Francisco, California, USA.
  • UCSF Center for Tuberculosis, University of California-San Francisco, San Francisco, California, USA.
  • URP7323 Pharmacologie et Évaluation des Thérapeutiques Chez l'Enfant et la Femme Enceinte, 21 Université Paris Cité, Paris, France.
  • Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

ORCID-Profile: Jordan T Brooks, Belén P Solans, Agathe Béranger, H Simon Schaaf, Louvina van der Laan, Anneke C Hesseling, Anthony J Garcia-Prats

Förderung

  • BENEFIT Kids

Zitieren

APA

Brooks, J. T., Solans, B. P., Béranger, A., Schaaf, H. S., van der Laan, L., Sharma, S., Furin, J., Draper, H. R., Hesseling, A. C., Garcia-Prats, A. J., & Savic, R. M. (2024). Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis. Clinical Infectious Diseases, 79(6), 1495-1502. https://doi.org/10.1093/cid/ciae497

Vancouver

Brooks JT, Solans BP, Béranger A, Schaaf HS, van der Laan L, Sharma S, et al. Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis. Clinical Infectious Diseases. 2024;79(6):1495-1502. doi:10.1093/cid/ciae497

BibTeX
@article{Brooks2024,
  author = {Brooks, Jordan T and Solans, Belén P and Béranger, Agathe and Schaaf, H Simon and van der Laan, Louvina and Sharma, Sangeeta and Furin, Jennifer and Draper, Heather R and Hesseling, Anneke C and Garcia-Prats, Anthony J and Savic, Radojka M},
  title = {Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {79},
  number = {6},
  pages = {1495--1502},
  doi = {10.1093/cid/ciae497}
}
Kostenlos starten →